New Data on Long-Acting Investigational Medication for HIV Prevention

Scientist holds vial of experimental HIV prevention medicine

We’ve announced topline results from an interim analysis of a clinical trial of our investigational medication for HIV prevention. This is the second Phase 3 trial to demonstrate the efficacy and safety profile for this medication. The first trial, PURPOSE 1 — which studied HIV prevention among cisgender women in sub-Saharan Africa — was unblinded early because it met key efficacy endpoints.

Our Purpose

Scientific Innovation

We discover, develop and deliver medicines for the world’s most devastating diseases, from viruses to cancer to inflammatory conditions.

A young woman and an older woman embracing

Access & Health Equity

We’re partnering with communities around the world to remove societal barriers to care, improve health equity and make our medicines available to those who need them most.

A smiling Gilead employee in a manufacturing facility

Our People & Culture

We foster an environment of inclusion and growth where our 18,000+ employees around the world are empowered to make a real impact.

We’ve been taking on the world’s biggest health challenges for more than 35 years. We continue to set and achieve ambitious goals to create a healthier world for all people.

Our Mission